Search


Current filters:




Start a new search
Add filters:

Use filters to refine the search results.


Results 1-10 of 16 (Search time: 0.004 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2002Mannose-binding lectin gene polymorphisms are associated with major infection following allogeneic hemopoietic stem cell transplantationMullighan, C.; Heatley, S.; Doherty, K.; Szabo, F.; Grigg, A.; Hughes, T.; Schwarer, A.; Szer, J.; Tait, B.; To, L.; Bardy, P.
2002High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistanceBranford, S.; Rudzki, Z.; Walsh, S.; Grigg, A.; Arthur, C.; Taylor, K.; Herrmann, R.; Lynch, K.; Hughes, T.
2001Effect of down syndrome on the dimensions of dental crowns and tissuesBell, E.; Townsend, G.; Wilson, D.; Kieser, J.; Hughes, T.
2000Engraftment of T-cell-depleted allogeneic haematopoietic stem cells using a reduced intensity conditioning regimenCraddock, C.; Bardy, P.; Kreiter, S.; Johnston, R.; Apperley, J.; Marks, D.; Huber, C.; Kolbe, K.; Goulding, R.; Lawler, M.; Goldman, J.; Hughes, T.; Derigs, G.
2008Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemiale Coutre, P.; Ottmann, O.; Giles, F.; Kim, D.; Cortes, J.; Gattermann, N.; Apperley, J.; Larson, R.; Abruzzese, E.; O'Brien, S.; Kuliczkowski, K.; Hochhaus, A.; Mahon, F.; Saglio, G.; Gobbi, M.; Kwong, Y.; Baccarani, M.; Hughes, T.; Martinelli, G.; Radich, J.; et al.
2004Non-HLA immunogenetic polymorphisms and the risk of complications after allogeneic hemopoietic stem-cell transplantationMullighan, C.; Heatley, S.; Doherty, K.; Szabo, F.; Grigg, A.; Hughes, T.; Schwarer, A.; Szer, J.; Tait, B.; To, L.; Bardy, P.
2003Selected CD34 blood cell allografts for older patients: low transplant-related mortality, graft failure and acute GvHDRoberts, M.; Dyson, P.; Rawling, C.; Thorp, D.; Rawling, T.; White, D.; Horvath, N.; Bardy, P.; Hui, C.; Dart, G.; To, L.; Hughes, T.
2008Daclizumab has poor efficacy in steroid-refractory severe acute graft-versus-host disease: a single centre experience with 12 allograft patientsHui, C.; Sia, H.; Mangos, H.; Horvath, N.; Lewis, I.; Hughes, T.; To, L.; Bardy, P.
2003Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemiaO'Brien, S.; Guilhot, F.; Larson, R.; Gathmann, I.; Baccarani, M.; Cervantes, F.; Cornelissen, J.; Fischer, T.; Hochhaus, A.; Hughes, T.; Lechner, K.; Nielsen, J.; Rousselot, P.; Reiffers, J.; Saglio, G.; Shepherd, J.; Simonsson, B.; Gratwohl, A.; Goldman, J.; Kantarjian, H.; et al.
2003Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemiaHughes, T.; Kaeda, J.; Branford, S.; Rudzki, Z.; Hochhaus, A.; Hensley, M.; Gathmann, I.; Bolton, A.; van Hoomissen, I.; Goldman, J.; Radich, J.